What changed
$JNJ — WATCHLIST 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $24.1B | EPS $2.70 vs $2.68 🟢
💡 Consensus likely incorporates modest earnings growth; the slight Q1 beat and raised guidance are not enough to justify a re-rating from already premium multiples. The market may be overestimating growth durability in the face of upcoming biosimilar headwinds.
📉 Reward/risk: 1.63:1
🏢 Business Quality: 9/10 - JNJ has a wide moat with pharma, medtech, and consumer health, strong cash flows, and AAA credit rating.
📊 Valuation: rich - Current P/E 27.6x vs historical median 21.8x, at top of 10-year range. EV/EBITDA likely above peers.
🔮 Catalyst: Post-earnings estimate revisions from analysts after raised 2026 outlook.
💰 Entry: $235.18, stop $220, target $260
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/JNJ0617